Objective: To study the therapeutic efficacy of Rosuvastatin for patients with carotid atherosclerotic plaques complicated by cerebral infarction. Methods: A total of 120 patients with carotid atherosclerotic plaques complicated by cerebral infarction were randomly divided into control group (60 cases) and treatment group (60 cases). The control group was given conventional therapy against the platelet aggregation and the treatment group was given Rosuvastatin 20 mg ·d-1 on basis of conventional therapy. The scores of carotid atherosclerotic plaques, the levels of blood lipid and C-reactive protein (CRP) were compared between the two groups. Results: After the follow-up of 6 and 12 months, the scores of carotid atherosclerotic plaques in the treatment group (3.42±0.45 ,3.23±0.57) were significantly less than the control group (4.07 ± 0.47,4.12±0.38) and in the treatment group, the level of blood lipid at the follow-up after 3 months was reduced markedly, the level of C-reactive proteins [(4.86±3.54), (3.23±2.92) mmol/L] at the follow-up after 6 months was reduced markedly than the control group [(13.45±2.04),(13.32±2.11) mmol/L], the difference was significant (P<0.05). Conclusion: Rosuvastatin can markedly delay the progress of carotid atherosclerotic plaques and promote the elimination of carotid atherosclerotic plaques and lower the blood lipid level.%目的:研究瑞舒伐他汀对脑梗死合并颈动脉粥样硬化斑块的治疗作用.方法:将120例脑梗死合并颈动脉粥样硬化斑块患者随机分为对照组(60例)和治疗组(60例),对照组仅给予常规抗血小板聚集治疗,治疗组在常规抗血小板聚集治疗的基础上给予瑞舒伐他汀20 mg·d-1.比较两组经动脉粥样硬化斑块评分、血脂水平和血清C-反应蛋白水平变化.结果:治疗组6个月、12个月复诊时颈动脉斑块积分[(3.42±0.45)、(3.23±0.57)分]和对照组[(4.07±0.47)、(4.12±0.38)分]相比显著降低(P<0.05);3个月后血脂水平显著下降;6个月、12个月的治疗组C反应蛋白水平[(4.86±3.54)、(3.23±2.92)mmol/L)]较对照组[(13.45±2.04)、(13.32±2.11)mmol/L)]明显下降,差异有统计学意义(P<0.05).结论:瑞舒伐他汀可显著稳定动脉粥样硬化斑块,促进斑块消失,并有较强的降低血脂作用.
展开▼
